Title : Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies.

Pub. Date : 2014 Oct

PMID : 25149983






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic complications such as cataract and nephropathy. Resveratrol aldo-keto reductase family 1 member B1 Rattus norvegicus
2 The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic complications such as cataract and nephropathy. Resveratrol aldo-keto reductase family 1 member B1 Rattus norvegicus
3 The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic complications such as cataract and nephropathy. Resveratrol aldo-keto reductase family 1 member B1 Rattus norvegicus
4 The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic complications such as cataract and nephropathy. Resveratrol aldo-keto reductase family 1 member B1 Rattus norvegicus
5 METHODS: RSV was studied for its inhibitory activity against rat lens AR (RLAR) and rat kidney AR (RKAR) in vitro along with its ability to inhibit formation of AGEs. Resveratrol aldo-keto reductase family 1 member B1 Rattus norvegicus
6 METHODS: RSV was studied for its inhibitory activity against rat lens AR (RLAR) and rat kidney AR (RKAR) in vitro along with its ability to inhibit formation of AGEs. Resveratrol aldo-keto reductase family 1 member B1 Rattus norvegicus